October 2019 Midatech Pharma PLC ("Midatech" or the "Company") Issue of Equity for Midatech Employee Share Incentive Plan Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), the R&D biotechnology company focused on deliverin

("Midatech" or the "Company")

Issue of Equity for Midatech Employee

Share Incentive Plan

Midatech Pharma PLC (AIM: MTPH.L; Nasdaq:

MTP), the R&D biotechnology company focused on delivering innovative oncology and rare disease products to patients, today

announces that, conditional on admission to trading on AIM, it has issued and allotted 500,000 new ordinary shares of 0.005 pence

each in the Company ("Ordinary Shares"), which are to be purchased at nominal value by the Midatech Pharma Share Incentive

Plan, an employee share incentive trust.

Application has been made for the 500,000

new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will take place

at 8.00 a.m. on 8 October 2019. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares.

Following Admission, the Company will

have 409,899,613 Ordinary Shares in issue, none of which are held in treasury. Shareholders may use this figure as the denominator

for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest

in, the issued share capital of the Company.

For more information, please contact:

Midatech Pharma PLC (dual listed on LSE

AIM: MTPH; and NASDAQ: MTP) is an R&D company focused on Making Medicines Better' by improving delivery of drugs

in the body. The Company combines existing medications with its proprietary and innovative drug delivery technologies to provide

compelling oncology and rare disease products that have the potential to powerfully impact the lives of patients undergoing treatment

for life threatening diseases.

The Company has developed three in-house

technology platforms, each with its own unique mechanism to improve delivery of medications to sites of disease. All of the Company's

technologies have successfully entered human use in the clinic, providing important validation of the potential for each platform:

By improving biodelivery and biodistribution

of approved existing molecules, Midatech's unique R&D has the potential to make medicines better, lower technical risks,

accelerate regulatory approval and route to market, and provide newly patentable products. The platform nature of the technologies

allows the potential to develop multiple drug assets rather than being reliant on a limited number of programmes.

Midatech's headquarters and R&D facility

is in Cardiff, UK, and manufacturing operation in Bilbao, Spain. For more information please visit www.midatechpharma.com